One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Activity of First-Line Trastuzumab.
Griggs, Jennifer J. MD, MPH 1,
doi : 10.1200/JCO.22.02843
Volume 41(9) pgs. 1635-1791 March 20, 2023
JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002).
doi : 10.1200/JCO.23.00305
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
Vogel, Charles L.; Cobleigh, Melody A.; Tripathy, Debu; Gutheil, John C.; Harris, Lyndsay N.; Fehrenbacher, Louis; Slamon, Dennis J.; Murphy, Maureen; Novotny, William F.; Burchmore, Michael; Shak, Steven; Stewart, Stanford J.; Press, Michael
doi : 10.1200/JCO.22.02516
To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer.
CAR T-Cells for Cure in Pediatric B-ALL.
Gardner, Rebecca A. MD 1,; Shah, Nirali N. MD, MHSc 2,
doi : 10.1200/JCO.22.02345
Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?.
Grommes, Christian MD 1,2,
doi : 10.1200/JCO.22.02605
Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
Trapani, Dario MD 1,2,
doi : 10.1200/JCO.22.02477
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches
Where Are All the Women in Industry Advisory Boards?.
Shroff, Rachna T. MD 1,; Goodman, Karyn A. MD 2,; Mehnert, Janice M. MD 3,; Vose, Julie M. MD, MBA 4,; Moran, Susan E. MD 5,; Yessaian, Jennifer L. RN, MBA 6,; Baldo, Lance MD 7,; Alexander, Brian M. MD, MPH 8,; Highsmith, Quita B. MBA 9,; Mills, Jennifer M. PhD, MPH, MSW 8,; Kunz, Pamela L. MD 10,
doi : 10.1200/JCO.21.02219
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Laetsch, Theodore W. MD 1,2,,; Maude, Shannon L. MD, PhD 1,; Rives, Susana MD, PhD 3,; Hiramatsu, Hidefumi MD, PhD 4,; Bittencourt, Henrique MD, PhD 5,6,; Bader, Peter MD 7,; Baruchel, Andre MD 8,; Boyer, Michael MD 9,; De Moerloose, Barbara MD, PhD 10,; Qayed, Muna MD 11,; Buechner, Jochen MD, PhD 12,; Pulsipher, Michael A. MD 13,14,; Myers, Gary Douglas MD 15,; Stefanski, Heather E. MD, PhD 16,; Martin, Paul L. MD, PhD 17,; Nemecek, Eneida MD 18,; Peters, Christina MD 19,; Yanik, Gregory MD 20; Khaw, Seong Lin MBBS(Hons), PhD 21,; Davis, Kara L. DO 22,; Krueger, Joerg MD 23,; Balduzzi, Adriana MD 24,; Boissel, Nicolas MD, PhD 25,; Tiwari, Ranjan MSc 26,; O'Donovan, Darragh PhD 27,; Grupp, Stephan A. MD, PhD 1,2,
doi : 10.1200/JCO.22.00642
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
Wang, Tianyi MD 1; Tang, Yanjing MD, PhD 1; Cai, Jiaoyang MD, PhD 1; Wan, Xinyu MD 1; Hu, Shaoyan MD, PhD 2; Lu, Xiaoxi MD 3; Xie, Zhiwei MD 4; Qiao, Xiaohong MD 5; Jiang, Hui MD 6; Shao, Jingbo MD, PhD 6; Yang, Fan MD 2; Ren, Hong MD 7; Cao, Qing MD, PhD 8; Qian, Juan MD, PhD 7; Zhang, Jian MD 7; An, Kang MD 1; Wang, Jianmin MD 1; Luo, Chengjuan MD 1; Liang, Huanhuan BS 1; Miao, Yan PhD 1; Ma, Yani BS 1; Wang, Xiang PhD 1; Ding, Lixia BS 1; Song, Lili PhD 1; He, Hailong MD 2; Shi, Wenhua MD 2; Xiao, Peifang MD 2; Yang, Xiaomin MD 1; Yang, Jing MD 1; Li, Wenjie MD 1; Zhu, Yiping MD, PhD 3; Wang, Ningling MD 4; Gu, Longjun MD 1; Chen, Qimin MD 9; Tang, Jingyan MD, PhD 1; Yang, Jun J. PhD 10,; Cheng, Cheng PhD 11; Leung, Wing MD 12,; Chen, Jing MD, PhD 1; Lu, Jun MD 2; Li, Benshang MD, PhD 1; Pui, Ching-Hon MD 13,,
doi : 10.1200/JCO.22.01214
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter, Jurik A. BSc 1,2; Alig, Stefan K. MD 3,; Esfahani, Mohammad S. PhD 3,; Lauer, Eliza M. MD 1; Mitschke, Jan PhD 1,; Kurtz, David M. MD, PhD 3,; Kuhn, Julia MD 1; Bleul, Sabine 1; Olsen, Mari PhD 3; Liu, Chih Long PhD 3; Jin, Michael C. BS 3; Macaulay, Charles W. MSc 3; Neidert, Nicolas MD 4,5; Volk, Timo MD 6,; Eisenblaetter, Michel MD 7; Rauer, Sebastian MD 6,; Heiland, Dieter H. MD 4; Finke, Jurgen MD 1,; Duyster, Justus MD 1; Wehrle, Julius MD 1; Prinz, Marco MD 8,9,10; Illerhaus, Gerald MD 11,; Reinacher, Peter C. MD 12,13,; Schorb, Elisabeth MD 1,; Diehn, Maximilian MD, PhD 14,; Alizadeh, Ash A. MD, PhD 3,; Scherer, Florian MD 1,15,
doi : 10.1200/JCO.22.00826
Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification of patients at high risk for treatment failure is challenging.
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
Lannes, Romain PhD 1,2; Samur, Mehmet PhD 3; Perrot, Aurore MD, PhD 2,4,; Mazzotti, Celine MSc 1,2; Divoux, Marion MD 5,; Cazaubiel, Titouan MD 6; Leleu, Xavier MD, PhD 7,; Schavgoulidze, Anais PharmD 1,2; Chretien, Marie-Lorraine MD, PhD 8; Manier, Salomon MD, PhD 9,; Adiko, Didier MD 10,; Orsini-Piocelle, Frederique MD 11,; Lifermann, Francois MD 12; Brechignac, Sabine MD 13; Gastaud, Lauris MD 14; Bouscary, Didier MD, PhD 15; Macro, Margaret MD 16,; Cleynen, Alice PhD 17; Mohty, Mohamad MD, PhD 18,; Munshi, Nikhil MD 3,; Corre, Jill PharmD, PhD 1,2,; Avet-Loiseau, Herve MD, PhD 1,2,
doi : 10.1200/JCO.21.01987
Multiple myeloma (MM) is characterized by copy number abnormalities (CNAs), some of which influence patient outcomes and are sometimes observed only at relapse(s), suggesting their acquisition during tumor evolution.
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
Yadav, Siddhartha MD 1,; Boddicker, Nicholas J. PhD 2; Na, Jie MS 2; Polley, Eric C. PhD 3,; Hu, Chunling PhD 4; Hart, Steven N. PhD 2; Gnanaolivu, Rohan D. PhD 2; Larson, Nicole BS 2; Holtegaard, Susan BS 4; Huang, Huaizhi BS 5; Dunn, Carolyn A. BS 4; Teras, Lauren R. PhD 6; Patel, Alpa V. PhD 6,; Lacey, James V. PhD 7; Neuhausen, Susan L. PhD 7; Martinez, Elena PhD 8; Haiman, Christopher ScD 9; Chen, Fei PhD 9; Ruddy, Kathryn J. MD 1,; Olson, Janet E. PhD 2,; John, Esther M. PhD 10,11; Kurian, Allison W. MD 10,11,; Sandler, Dale P. PhD 12; O'Brien, Katie M. PhD 12; Taylor, Jack A. MD, PhD 12; Weinberg, Clarice R. PhD 12; Anton-Culver, Hoda PhD 13; Ziogas, Argyrios PhD 13; Zirpoli, Gary PhD 14; Goldgar, David E. PhD 15; Palmer, Julie R. ScD 14; Domchek, Susan M. MD 16,17,; Weitzel, Jeffrey N. MD 18,; Nathanson, Katherine L. MD 16,17,; Kraft, Peter PhD 19,; Couch, Fergus J. PhD 4,,
doi : 10.1200/JCO.22.01239
To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder, Mrinal M. MD 1,; Bauer, Todd M. MD 2,; Schwartz, Gary K. MD 3,; Weise, Amy M. DO 4; LoRusso, Patricia DO, PhD 5,; Kumar, Prasanna PhD 6,; Tao, Ben MS 6; Hong, Ying PhD 6,; Patel, Parul MSc 6,; Lu, Yasong PhD 6,; Lesegretain, Arnaud 6,; Tirunagaru, Vijaya G. PhD 7,; Xu, Feng MS 7,; Doebele, Robert C. MD, PhD 7,; Hong, David S. MD 8,,
doi : 10.1200/JCO.22.01285
This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers.
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
Fu, Siqing MD, PhD 1,; Yao, Shuyang MD, PhD 1; Yuan, Yuan MD, PhD 2,; Previs, Rebecca A. MD 3,; Elias, Anthony D. MD 4,; Carvajal, Richard D. MD 5,; George, Thomas J. MD 6,; Yuan, Ying PhD 1; Yu, Lihou PhD 1; Westin, Shannon N. MD 1,; Xing, Yan MD, PhD 2; Dumbrava, Ecaterina E. MD 1,; Karp, Daniel D. MD 1,; Piha-Paul, Sarina A. MD 1,; Tsimberidou, Apostolia M. MD, PhD 1,; Ahnert, Jordi Rodon MD 1,; Takebe, Naoko MD, PhD 7; Lu, Karen MD 1; Keyomarsi, Khandan PhD 1,; Meric-Bernstam, Funda MD 1,
doi : 10.1200/JCO.22.00830
Preclinical cancer models harboring CCNE1 amplification were more sensitive to adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification. Thus, we conducted this phase II study to assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors.
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
Wu, Hao-Xiang MD 1,2; Pan, Yi-Qian MD 1,2; He, Ye MD 1,2; Wang, Zi-Xian MD 1,2; Guan, Wen-Long MD 1,2; Chen, Yan-Xing PhD 1,2; Yao, Yi-Chen PhD 1,2; Shao, Ning-Yi MD, PhD 3,4; Xu, Rui-Hua MD, PhD 1,2,; Wang, Feng MD, PhD 1,2,
doi : 10.1200/JCO.22.01490
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European Medicines Agency, whereas the US Food and Drug Administration approved this regimen regardless of PD-L1 expression.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Yau, Thomas MD 1,,; Zagonel, Vittorina MD 2,; Santoro, Armando MD 3,4,; Acosta-Rivera, Mirelis MD 5,; Choo, Su Pin MD 6,; Matilla, Ana MD 7,8,; He, Aiwu Ruth MD 9,; Cubillo Gracian, Antonio MD, PhD 10,11; El-Khoueiry, Anthony B. MD 12,; Sangro, Bruno MD, PhD 13,; Eldawy, Tarek E. MD 14; Bruix, Jordi MD, PhD 15,; Frassineti, Giovanni Luca MD 16; Vaccaro, Gina M. MD 17,; Tschaika, Marina MD, PhD 18,; Scheffold, Christian MD, PhD 19,; Koopmans, Petra PhD 18; Neely, Jaclyn PhD 18,; Piscaglia, Fabio MD, PhD 20,
doi : 10.1200/JCO.22.00972
To investigate the safety and efficacy of nivolumab plus cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma.
Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors.
Wang, Xuexia PhD 1; Singh, Purnima MSc, PhD, MSPH 2; Zhou, Liting MS 2; Sharafeldin, Noha MD, MSc, PhD 2; Landier, Wendy PhD 2,; Hageman, Lindsey MPH 2; Burridge, Paul PhD 3; Yasui, Yutaka PhD 4; Sapkota, Yadav PhD 4; Blanco, Javier G. PhD 5; Oeffinger, Kevin C. MD 6; Hudson, Melissa M. MD 4,; Chow, Eric J. MD, MPH 7,; Armenian, Saro H. DO, MPH 8; Neglia, Joseph P. MD, MPH 9; Ritchey, A. Kim MD 10; Hawkins, Douglas S. MD 7,; Ginsberg, Jill P. MD 11; Robison, Leslie L. PhD 4; Armstrong, Gregory T. MD, MSCE 4,; Bhatia, Smita MD, MPH 2,,
doi : 10.1200/JCO.22.01527
Interindividual variability in the dose-dependent association between anthracyclines and cardiomyopathy suggests a modifying role of genetic susceptibility. Few previous studies have examined gene-anthracycline interactions.
CCNE1 Amplification as a Therapeutic Target.
Au-Yeung, George MBBS, PhD 1,2,,; Mileshkin, Linda MBBS, MD 1,2; Bowtell, David D.L. PhD 1,2,
doi : 10.1200/JCO.22.02267
Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update.
Lehrnbecher, Thomas MD 1,; Robinson, Paula D. MD, MSc 2; Ammann, Roland A. MD 3,4; Fisher, Brian DO, MSCE 5,; Patel, Priya RPh, MSc 2,6; Phillips, Robert MA, BMBCh 7; Beauchemin, Melissa P. PhD, MSN 8; Carlesse, Fabianne MD, PhD 9,; Castagnola, Elio MD 10,; Davis, Bonnie L. 11; Elgarten, Caitlin W. MD, MSCE 12; Groll, Andreas H. MD 13,; Haeusler, Gabrielle M. MBBS, PhD 14,15,16,; Koenig, Christa MD, PhD 3,4; Santolaya, Maria E. MD 17; Tissing, Wim J.E. MD, PhD 18,19; Wolf, Joshua MBBS, PhD 20,21,; Alexander, Sarah MD 22; Hu, Helen 2,23; Dupuis, L. Lee PhD 6,23,24,; Sung, Lillian MD, PhD 22,24,,
doi : 10.1200/JCO.22.02224
To update a clinical practice guideline (CPG) for the empiric management of fever and neutropenia (FN) in pediatric patients with cancer and hematopoietic cell transplantation recipients.
Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial.
Al Hadidi, Samer MD, MS; van Rhee, Frits MD, PhD
doi : 10.1200/JCO.22.02098
Reply to S. Al Hadidi et al.
Dimopoulos, Meletios A. MD; San-Miguel, Jesus MD, PhD
doi : 10.1200/JCO.22.02438
Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer.
Mo, Dun-Chang MD; Huang, Jian-Feng MD; Luo, Peng-Hui MD
doi : 10.1200/JCO.22.02398
Reply to D.-C. Mo et al.
Patil, Vijay Maruti MBBS, MD, DM; Noronha, Vanita MBBS, MD, DM; Prabhash, Kumar MBBS, MD, DM; Bhattacharjee, Atanu PhD
doi : 10.1200/JCO.22.02741
